Overview

Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors

Status:
Completed
Trial end date:
2020-09-29
Target enrollment:
Participant gender:
Summary
This was a single arm phase Ib study to evaluate the safety and efficacy of combined Tomuzotuximab and Gatipotuzumab therapy in patients with metastatic solid tumors expressing EGFR for whom no standard treatment is available. Patients who had relapsed following their most recent line of chemotherapy and who met all other entry criteria at Screening were enrolled to receive Tomuzotuximab and Gatipotuzumab in combination. During the extension phase, instead of Tomuzotuximab a commercially avalaible anti-EGFR antibody, i.e. Cetuximab (including any approved biosimilar), Panitumumab, or Necitumumab could be given to patients with cancers for which their use is approved.
Phase:
Phase 1
Details
Lead Sponsor:
Glycotope GmbH
Treatments:
Antibodies
Cetuximab
Necitumumab
Panitumumab